Sort
39,280 grants matching “leukemia”
Stanford University NCTN- Network Lead Academic Site
$547,394Heather Ann Wakelee · Stanford University · U10 · FY2017 · CA
Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
$547,355Vincent Collins Ofuka Njar · Thomas Jefferson University · R01 · FY2010 · CA
Novel Regulation of Oncogenic NRAS Signaling in Myeloid Malignancies
$547,313Wei Tong · Children'S Hosp Of Philadelphia · R01 · FY2025 · CA
lncRNA regulation of glioblastoma progression and therapeutic resistance
$547,221Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · NS
lncRNA regulation of glioblastoma progression and therapeutic resistance
$547,221Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · NS
Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity
$547,212Won Hee Lee · University Of Arizona · R01 · FY2023 · HL
Discovery of Somatic Noncoding Variants that Serve as Drivers in Pediatric Cancers
$547,191Jinghui Zhang · St. Jude Children'S Research Hospital · R01 · FY2019 · CA
The Clathrin Coated Vesicle Cycle
$547,187Sandra L. Schmid · Scripps Research Institute, The · R01 · FY2010 · MH
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation
$547,180Catherine Choy Smith · University Of California, San Francisco · R01 · FY2025 · CA
Ubiquitin And SUMO Post-Translational Modifications In Development And Disease
$547,096Michael Kuehn · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Antibody Engineering for Therapy and Diagnosis of Hematologic Malignancies
$547,078Christoph Rader · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Discovery of Drugs, Targets, and Target Strategies for Immunotherapy of CLL
$547,078Christoph Rader · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Role of miR155 in Leukemogenesis
$547,067Carlo M Croce · Ohio State University · R01 · FY2008 · CA
Pooling and expansion of Chronic Lymphocytic Leukemia GWA data
$547,062Susan L Slager · Mayo Clinic Rochester · R01 · FY2011 · CA
Optimization of small molecule integrin activators to enhance cord blood transplant
$547,028Peter Vanderslice · Texas Heart Institute · R33 · FY2023 · HL
(PQC2) Localization as a determinant of cancer dormancy
$547,017Charles P Lin · Massachusetts General Hospital · R01 · FY2015 · CA
EZH2 in cancer biology and novel inhibitors
$546,990Jun Qi · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Causes and consequences of genomic instability in myelodysplasia
$546,872Stanley Chun-Wei Lee · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Clinical Trials Exploiting NK Cell Activity
$546,585Daniel J Weisdorf · University Of Minnesota · P01 · FY2018 · CA
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance
$546,497Omar Abdel-Wahab · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA
Administrative Core
$546,492Sumithra Jay Mandrekar · Mayo Clinic Rochester · U10 · FY2022 · CA
JHU- Optimal regimen development on a Ribosome inhibitor backbone.
$546,375Eric L Nuermberger · Global Alliance For Tb Drug Development · U19 · FY2023 · AI
Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
$546,364Michael J Borowitz · Johns Hopkins University · R01 · FY2008 · CA
Activation of Proto-Oncogenes by Chromosomal Translocation
$546,342Peter Aplan · Division Of Clinical Sciences - Nci · ZIA · FY2014 · CA
Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Label
$546,302Michael Rod Zalutsky · Duke University · P01 · FY2015 · CA